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doi:10.1Objective: Pulmonary dysfunction is common in transfused patients recovering from heart surgery. Plasma trans-
fusion from female donors has been linked with rare catastrophic lung injury, but its relationship with outcome
after cardiac surgery is poorly understood. We examined whether plasma donor gender is related to postcardiac
surgery pulmonary dysfunction and death or prolonged hospitalization.
Methods: In this retrospective case-control study, cardiac surgery candidates who received plasma periopera-
tively from only female donors were compared with male-only recipients who were matched for the number
of units transfused and surgery date.
Results: In a dataset of 2157 recipients, there were no blood bank–reported complications, but escalating plasma
transfusion was associated with increased 30-day mortality (odds ratio, 1.52 per unit; P¼ .0001). From the 1069
recipients receiving plasma exclusively from female or male donors, 390 matched pairs were identified. Recip-
ients of female compared with male donor plasma had a lower incidence of pulmonary dysfunction (5.9% vs
10.8%; P ¼ .01) and death or hospitalization more than 10 days (9% vs 16.4%; P ¼ .002) but similar long-
term survivals.
Conclusions: Escalating plasma transfusion was associated with 30-day mortality, but female donor plasma re-
cipients had less pulmonary dysfunction and fewer poor outcomes compared with male-only recipients. Although
our retrospective study findings neither support nor refute a strategic policy to exclude female donor plasma to
reduce catastrophic transfusion-related acute lung injury, they raise concern that such a policy may have unantic-
ipated effects on outcome in patients undergoing cardiac surgery and highlight a need for additional studies in this
and other patient groups. (J Thorac Cardiovasc Surg 2010;140:1353-60)P
MPulmonary responses to plasma transfusion include circula-
tory overload, acute lung injury, and dyspnea of unknown
cause.1 Cardiac surgery is a suitable setting to examine the
spectrum of transfusion-related pulmonary dysfunction, be-
cause it consumes more than 20% of transfusions in the
United States. Although respiratory risk is rarely considered
in the perioperative decision to transfuse patients undergo-
ing heart surgery, their recovery is commonly complicated
by pulmonary dysfunction, and adult respiratory distress
syndrome (ARDS) occurs after up to 2% of procedures.2
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The Journal of Thoracic and Cara transfusion is typically indistinguishable from ARDS
and, although rarely reported (estimated 200 fatalities per
year in the United States),3 represents the leading cause of
death from hemotherapy. Although such cases are most of-
ten related to plasma and occasionally reported in patients
undergoing cardiac surgery, of particular interest are the
more common but milder nonspecific pulmonary effects
that typically go unattributed to transfusion but may also in-
fluence outcome.4,5 An intensive care unit (ICU) study in
which lung injury identified within hours of transfusion in
8% of patients was associated with subsequent respiratory
support needs, extended ICU and hospital stays, and mortal-
ity risk highlights the potential for links between plasma
transfusion and subsequent hospital course.4
Antileukocyte antibodies are more common in women,6
presumably because of placental sensitization, and have
been linked to cases of transfusion fatalities.1,7 In the past
several years, this has prompted some national transfusion
agencies (eg, the United Kingdom and United States) to re-
strict the use of female donor plasma on the basis of the
mechanism for lung injury attributed to donor antileukocyte
antibodies (antihuman leukocyte antigen class I, antihuman
leukocyte antigen class II, and antigranulocyte).1,7,8 How-
ever, the relative importance of leukocyte antibodies com-
pared with other injury mechanisms (eg, nonantibodydiovascular Surgery c Volume 140, Number 6 1353
Abbreviations and Acronyms
ARDS ¼ adult respiratory distress syndrome
ICU ¼ intensive care unit
TRALI ¼ transfusion-related acute lung injury
Perioperative Management Welsby et al
P
Mmediated, ‘‘2 hit’’ hypothesis) and their relevance to the
milder pulmonary effects of plasma transfusion are un-
known.4
Although the need for research into transfusion recipient
epidemiology and outcomes is acknowledged,9 no studies
have yet evaluated the effects of a policy restricting female
donor plasma use in patients undergoing cardiac surgery. A
single study identifying fresh-frozen plasma transfusion as
an independent risk factor for post-cardiac surgery renal fail-
ure did not assess donor gender.10 To better understand the
relationship of donor gender, plasma transfusion, postopera-
tive pulmonary dysfunction, and outcome after cardiac sur-
gery, we assessed Red Cross donor blood bank transfusion
and prospectively collected quality assurance data for a co-
hort of patients undergoing aortocoronary bypass surgery.
MATERIALS AND METHODS
The patient population included all adult primary, non-emergency, aor-
tocoronary bypass surgery procedures performed at Duke University Med-
ical Center between June 1, 1995, and June 30, 2002; long-term follow-up
was to February 28, 2007. Surgery dates were selected from a period preced-
ing concerns regarding donor gender. The primary analysis was performed
using a paired subset of patients from those receiving plasma exclusively
from female or male donors, matched for the number of plasma units trans-
fused and nearest surgery date using an iterative computer algorithm. The
maximum date difference between surgery dates was restricted to 1 year,
and no patient was included more than once. Platelets, cryoprecipitate,
and other less commonly used blood products containing plasma were not
included in the match because pooling of platelet units from multiple donors
precluded donor gender assignment.
Standard practice included intraoperative administration of an antifibri-
nolytic therapy; most often this was e aminocaproic acid, although because
of surgeon preference a few patients instead received aprotinin. The use of
cell-saver technology to return washed shed red blood cells to the patient
was routine. All plasma units were collected, thawed, and transfused within
approved regulatory time guidelines, and plasma transfusion decisions were
aided by local guidelines and use of activated clotting time, fibrinogen level,
thromboelastograph, prothrombin, and partial thromboplastin time tests.
There was a general approach to avoid unnecessary use of blood products.
Data on the gender of blood donors were not available to Blood Bank per-
sonnel or caregivers. The standard Blood Bank response to a request for
plasma is to provide a suitable plasma unit without regard for characteristics
other than ABO compatibility.
We accessed the Duke Databank for Cardiovascular Diseases to obtain
patient characteristics and perioperative information. The Databank is pro-
spectively compiled during the hospital stay from contemporaneous medi-
cal records, custom datasheets, and laboratory results; quality assurance
includes subsequent random chart review for completeness. Survival data
were provided by the Duke Clinical Research Institute Follow-up Group.11
Only patients receiving plasma units that were successfully cross-referenced
with the American Red Cross donor database were included in the study.
Computerized cross-referencing between the Carolinas Region American1354 The Journal of Thoracic and Cardiovascular SurRed Cross database and the Duke Databank provided donor characteristics
for plasma units including gender. A blinded, manual research of Red Cross
records for 20 randomly selected plasma units found 100% data concor-
dance with computerized data including donor gender. Institutional and
Red Cross review boards approved data access with patient consent waived
for use in the research.
In-hospital complications were recorded using Society of Thoracic Sur-
geons criteria (see Appendix 1). The a priori defined primary end point was
pulmonary dysfunction, a composite of pulmonary edema, pneumonia, and
ARDS. Notably, this end point generally evaluates clinically evident pulmo-
nary dysfunction and does not focus on catastrophic transfusion-related
acute lung injury (TRALI). A search was also made for voluntary reporting
to the Blood Bank of any transfusion reaction that was diagnosed as TRALI
by Blood Bank physicians according to the definition at the time. Secondary
end points were death within 30 days or prolonged hospital stay (>10 days
postoperative)12 and long-term survival. Other postoperative complications
were recorded, including neurologic (stroke or transient ischemic attack),
cardiac (atrial or ventricular arrhythmia, cardiac arrest), infectious (positive
blood culture, leg wound infection, sternal wound infection, mediastinitis,
or urinary tract infection), and renal (dialysis).
Statistical Analysis
The matched patient groups were compared for demographic factors and
primary and secondary outcomes using generalized estimating equations for
paired data and paired t tests for group comparisons of categoric and contin-
uous variables, respectively. Kaplan–Meier log rank test and Cox propor-
tional hazards regression analysis adjusted for the Hannan mortality risk
score13 were used to evaluate long-term survival.
Additional descriptive analyses included the unmatched dataset of
plasma recipients and all plasma units. The ratio of female-to-male plasma
donor units was calculated for each recipient and averaged for each compli-
cation group. For example, a patient receiving 2 female and 4 male donor
plasma units would have a 67% male donor ratio. For each complication,
the female-to-male ratio for the complication group was compared with
all other patients using multivariable logistic regression models adjusting
for number of plasma units transfused and preoperative Hannan mortality
risk score.13,14 Statistical analyses were performed using SAS version
8.02 (SAS Inc, Cary, NC).
RESULTS
During the study period, there were 8743 consecutive pri-
mary non-emergency aortocoronary bypass surgery proce-
dures and 6850 plasma units transfused. Of identified
plasma units, 6541 (96%), involving 2157 plasma recipi-
ents, were successfully cross-referenced with the American
Red Cross donor database. No transfusion reactions from
this cohort of patients were reported to the blood supplier
for TRALI evaluation. Female donors provided 2917 units
(44.6%), and 1069 patients received plasma from exclu-
sively male or exclusively female donors. In addition to
platelets and cryoprecipitate, a small number of other
plasma-containing units were transfused, including cryopre-
cipitate-poor plasma (n ¼ 7), plasma frozen within 8 to 24
hours of collection (n ¼ 17), and other plasma-containing
units (n ¼ 37).
The 30-day mortality rate for plasma recipients was 132 of
2157 (6%). The number of plasma units transfused was
strongly associated with patient mortality risk, with
a 1.52-fold increased likelihood of death with each unit
(95% confidence interval, 1.23–1.87; P ¼ .0001).gery c December 2010
TABLE 1. Patient, procedural, and transfusion characteristics in a matched analysis of patients undergoing aortocoronary bypass surgery
receiving plasma from male or female donors
Transfused plasma
Female donor only (n ¼ 390) Male donor only (n ¼ 390) P value
Patient demographic variables
Age, mean (SD), y 65 (10) 66 (10) .51
Gender, no. (% female) 102/390 (26) 144/390 (37) .002
Height, mean (SD), cm 170.8 (11.1) 169.2 (11.3) .12
Weight, mean (SD), kg 82.7 (18) 78.2 (17) .001
Ethnicity (% non-Caucasian) 35/390 (9) 54/390 (14) .03
% ABO blood types (O/A/B/AB) 46/41/9/4 43/42/11/4 .68
Rhesus blood type (% Rhþ) 338/390 (87) 348/390 (89) .27
Preoperative comorbidities
Diabetes, no. (%) 134/390 (34) 131/390 (34) .83
Hypertension, no. (%) 268/390 (69) 280/390 (72) .35
Smoking history, no. (%) 155/390 (40) 160/390 (41) .7
Previous CHF, no. (%) 71/390 (18) 77/390 (20) .58
Previous stroke, no. (%) 42/390 (11) 60/390 (16) .02
Previous MI, no. (%) 132/390 (33) 121/390 (31) .4
Baseline serum creatinine, mg/dL, mean (SD) 1.21 (0.70) 1.35 (1.28) .13
Hannan mortality risk index12 (SD) 0.03 (0.05) 0.03 (0.04) .36
Charlson comorbidity index13 (SD) 0.86 (1.13) 0.88 (1.19) .81
Procedural variables
Preoperative intravenous heparin, no. (%) 158/374 (42) 181/367 (49) .03
No. of bypass grafts, mean (SD) 3.3 (0.8) 3.3 (0.9) .29
CPB duration, min, mean (SD) 116 (39) 119 (44) .35
Transfusion characteristics
Fresh-frozen plasma, no. units, mean (SD) 1.65 (0.76) 1.65 (0.76) –
No. of units 1/2/3/>3 189/167/16/18 189/167/16/18 –
% donor gender F/M 100 / 0 0 / 100 –
Platelets no. (SD) 0.79 (0.75) 0.84 (0.82) .34
Number of units 0/1/2/3/>3 149/182/53/4/2 141/188/48/7/6
Mean age of units transfused (d) 3.36 (1.10) 3.19 (0.08) .13
Packed red blood cells 3.15 (1.27) 3.26 (1.21) .18
No. of units 0/1/2/3/>3 27/26/48/51/238 29/11/42/54/254
Mean age of units transfused (d) 16.47 (10.13) 16.95 (9.92) .15
Cryoprecipitate no. (SD) 0.23 (0.48) 0.28 (0.53) .18
No. of units 0/1/2/3 307/74/9/0 293/84/12/1
CHF, Congestive heart failure; MI, myocardial infarction; CPB, cardiopulmonary bypass; SD, standard deviation.
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MFrom the population of 1069 patients receiving exclusively
male or female donor plasma, 780 were matched by number
of plasma units and the nearest surgery date (390 pairs;
Table 1) for inclusion in the primary analysis; the median
pair difference in surgery date was 5 days, with a maximum
of 343 days. The median follow-up time was 742 days (max-
imum 2247 days). Fifteen patients in each group received
aprotinin. The average age of transfused platelets and red
blood cells were similar between the matched groups (Table
1). During the follow-up period, 93 and 109 deaths occurred
in the female and male plasma donor groups, respectively.
The likelihood of receiving a platelet transfusion was sim-
ilar between groups (P ¼ .44), with the majority of patients
receiving none. Predicted mortality using the Hannan13 risk
score was similar between groups (3.2%  0.5% female vs
3.5%  0.4% male plasma recipients, P ¼ .36; Table 1).The Journal of Thoracic and CarThe primary end point, pulmonary dysfunction (pulmo-
nary edema, pneumonia, or ARDS), was less common in re-
cipients of plasma from female compared with male donors
(5.9% vs 10.8%; P¼ .01, Table 2, Figure 1, A). Female do-
nor plasma recipients were also less likely to have a pro-
longed postoperative hospital stay or death within 30 days
(9.0% vs 16.4%; P ¼ .002, Table 2, Figure 1, C) and had
fewer infectious complications (1% vs 4%, P ¼ .01). Ad-
justed analyses accounting for differences between groups
(gender, weight, ethnicity, history of stroke, and preopera-
tive heparin therapy) found similar associations of male-
only plasma with pulmonary dysfunction (P¼ .04) and death
or prolonged hospital stay (P ¼ .007). The relative prepon-
derance of respiratory complications in male-only plasma re-
cipients was consistent when depicted by groups with
escalating numbers of plasma units transfused and wasdiovascular Surgery c Volume 140, Number 6 1355
TABLE 2. Postoperative complications in a matched analysis of
patients undergoing aortocoronary bypass surgery receiving plasma
from male or female donors
Transfused plasma
Female donor
only (n ¼ 390)
Male donor
only (n ¼ 390)
P
value
Pulmonary dysfunction, no. (%) 23/390 (6) 42/390 (11) .01*
Pulmonary edema, no. (%) 22/390 (6) 32/390 (8)
Pneumonia, no. (%) 3/390 (1) 10/390 (3)
ARDS, no. (%) 2/390 (1) 4/390 (1)
Death or prolonged stay, no. (%) 35/390 (9) 64/390 (16) .002y
Hospital stay  10 d, no. (%) 26/390 (7) 52/390 (13)
30-d mortality, no. (%) 11/390 (3) 18/390 (5)
Cardiac, no. (%) 99/390 (25) 107/390 (27) .50
Atrial arrhythmia, no. (%) 93/390 (24) 90/390 (23)
Ventricular arrhythmia, no. (%) 8/390 (2) 17/390 (4)
Cardiac arrest, no. (%) 4/390 (1) 6/390 (2)
Neurologic, no. (%) 10/389 (3) 10/388 (3) .99
Stroke, no. (%) 7/389 (2) 10/388 (3)
Transient ischemic attack,
no. (%)
4/389 (1) 0/388 (0)
Major infection,z no. (%) 3/389 (1) 14/388 (4) .01
Positive blood culture, no. (%) 1/389 (0) 5/388 (1)
Leg wound infection, no. (%) 1/389 (0) 4/388 (1)
Sternal wound infection, no. (%) 1/362 (0) 3/364 (2)
Mediastinitis, no. (%) 0/389 (0) 0/388 (0)
Minor infection
Urinary tract infection, no. (%) 8/389 (2) 11/388 (3) .47
Renal
Dialysis, no. (%) 4/390 (1) 5/390 (1) .74
ARDS, Adult respiratory distress syndrome. See Appendix 1 for definition of
complications. Analyses adjusted for gender, weight, ethnicity (Caucasian vs non-
Caucasian), history of stroke, and intravenous heparin therapy were *P ¼ .04 for
pulmonary dysfunction and yP ¼ .007 for death or prolonged stay. zMajor infections
excluding pneumonia.
FIGURE 1. Postoperative pulmonary dysfunction rates in matched
patients undergoing aortocoronary bypass surgery grouped by contributing
types of complications (A) and the number of units they received (B) (1, 2,
or>2 units) reflect an excess of pulmonary complications in equivalent re-
cipients of male relative to female donor plasma. Major complications
(30-day mortality or hospitalization>10 days) are also more common in
equivalent recipients of male relative to female donor plasma (C).
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Msuggestive of a dose effect (Figure 1, B). Other perioperative
complications are presented in Table 2. Kaplan–Meier
survival estimates suggest a trend toward longer survival in
female compared with male donor plasma recipients (log-
rank test, P ¼ .09). However, this effect is not supported
by analysis of the hazard ratio adjusted for Hannan score,
gender, weight, previous stroke, preoperative heparin
therapy, and ethnicity (Caucasian vs non-Caucasian), which
is 0.90 (95% confidence interval, 0.67–1.20; P ¼ .47)
(Figure 2).
Secondary analyses in the larger population of all plasma
recipients (n ¼ 2157), to compare donor ratios (female-to-
male) in patients with and without complications, supported
concerns regarding adverse outcomes associated with trans-
fusion of male donor plasma from our primary findings
(Table 3). There was a higher likelihood of receiving plasma
from a male donor in patients with pulmonary dysfunction
(n¼ 201, 60.9% vs 54.8%, P¼ .03) and prolonged hospital
stay or death within 30 days (n ¼ 366, 59.1% vs 54.6%,
P ¼ .02) compared with uncomplicated patients. Notably,1356 The Journal of Thoracic and Cardiovascular Surthe pattern of increased major infectious complications in
male-only recipients noted in our matched analysis was
not present in this analysis. Other postoperative complica-
tions are presented in Table 3.gery c December 2010
FIGURE 2. Kaplan–Meier estimates of survival in recipients of female
compared with male donor plasma, log-rank test P ¼ .09. Hazard ratio
for female donor plasma, as estimated by the Cox proportional hazards
model, adjusted for Hannan score, gender, weight, ethnicity (Caucasian
vs non-Caucasian), previous stroke, and preoperative heparin therapy is
0.90; 95% confidence interval, 0.67–1.20; P ¼ .47.
TABLE 3. Data including all 2157 aortocoronary bypass surgeries
comparing the likelihood of a transfused plasma unit coming from
a female donor in patients who did or did not have respiratory and
other postoperative complications
Total population
n ¼ 2157
Complication
(% plasma units
from female donor)
No complication
(% plasma units
from female donors)
P
value
Complication category
Specific condition
Respiratory (n ¼ 201) 39.1 45.2 .03
Pulmonary edema
(n ¼ 159)
37.3 44.9
Pneumonia (n ¼ 57) 44.4 44.2
ARDS (n ¼ 19) 44.1 44.2
Death or prolonged
stay (n ¼ 366)
40.9 45.4 .02
Hospital stay  10 d
(n ¼ 279)
40.7 45.2
30-d mortality
(n ¼ 132)
41.7 44.8
Cardiac (n ¼ 467) 44.7 44.6 .97
Neurologic (n ¼ 138) 41.7 44.8 .34
Serious infection*
(n ¼ 84)
41.6 44.7 .46
Acute kidney injuryy
(n ¼ 308)
46.9 43.4 .15
ARDS, Adult respiratory distress syndrome. Patients with postoperative respiratory
complications and poor outcome (death or prolonged stay) were more likely to receive
plasma from a male donor. See Appendix 1 for definition of complications. *Infections
excluding pneumonia. yPreoperative to postoperative serum creatinine increase
greater than 50%.
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MDISCUSSION
Although pulmonary dysfunction was common (8%) and
strongly associated with plasma transfusion in our study of
patients undergoing cardiac surgery, we found no link be-
tween female donor plasma and increased complications.
In fact, plasma from male donors was associated with worse
outcome. Matched analysis of female- and male-only donor
plasma recipients revealed less pulmonary dysfunction and
fewer poor outcomes (hospitalization >10 days or death
within 30 days), but no difference in long-term survival
for recipients of female donor plasma. In addition, our pri-
mary findings were supported by a consistent excess of pul-
monary complications in male compared with female donor
plasma recipients when patients were grouped by number of
plasma units received in a pattern suggestive of a dose effect.
Finally, a secondary assessment of the larger unmatched
sample of all patients receiving plasma from male or female
donors also supported our primary findings of less pulmo-
nary dysfunction and fewer poor outcomes with female do-
nor plasma. Our study is not designed to evaluate
catastrophic TRALI episodes but raises concern that any re-
duction in this rare condition related to policies restricting
female donor plasma use may have important unrecognized
adverse consequences in patients undergoing cardiac
surgery.
Reductions in reported deaths related to catastrophic
TRALI that may be a consequence of ‘‘male only’’ plasma
policies are good news but do not reflect overall outcomes
(including deaths from other causes) in large patient groups.
Agencies reviewing methods to assess changes in transfu-
sion policy describe epidemiologic studies as a ‘‘timely
and highly desirable’’ analytic approach despite their poten-
tial for bias and confounding.9 Support from a broad assess-
ment of outcomes is needed to endorse the implementation
of transfusion policies restricting female donor plasma use,The Journal of Thoracic and Cara policy that was developed primarily from ‘‘circumstan-
tial’’3 serologic evidence (linking leukocyte antibodies
with fatal lung injury/TRALI).6 One explanation for our
findings could be that patients undergoing cardiac surgery
are a special case with regard to ‘‘male only’’ plasma and
complication rates, but large outcome studies in other patient
groups will be required to explore whether our findings are
isolated or spurious.
Lung injury observed within hours of plasma transfusion
in critically ill patients is common (8%–10%) and highly
associated with poor outcome.15 Although no reports have
examined donor gender with regard to lung function in car-
diac surgery cohorts, 3 studies exist in critically ill pa-
tients.4,16,17 As in our study, each report confirms strong
associations between escalating plasma use and lung injury,
but there is no consistent pattern with regard to donor gen-
der. An ICU investigation similar in design to the current
study compared 224 paired plasma recipients (3 units),
matched for donor gender, and found no difference in lung
injury but more ventilator-free days (28 vs 27; P ¼ .006)
in male-only recipients.17 A second report from the same
group identified more lung injury in 901 medical ICU pa-
tients with female compared with male donor plasma
(odds ratio, 5.09 vs 1.60).4 Finally, in a British cohort ofdiovascular Surgery c Volume 140, Number 6 1357
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M211 consecutive ruptured aortic aneurysm surgeries over an
8-year period, a blood supply change to male-only plasma
was associated with a decrease in lung injury (36% vs
21%; P ¼ .04) but no change in time to tracheal extubation
or 30-day survival.16 Unfortunately, transfusion policy
changes during this last study are difficult to separate from
other diagnostic and surgical practice changes during the
same period. In our study of patients undergoing cardiac sur-
gery, we found less pulmonary dysfunction and better out-
come (less prolonged hospitalization or death within 30
days) but no difference in long-term survival in recipients
of female donor plasma. Collectively, these investigations
provide insufficient consensus to support simple understand-
ing of the relationship among plasma transfusion, donor gen-
der, pulmonary dysfunction, and outcome in critically ill
patients.
Our study has limitations, including lack of power to eval-
uate rare catastrophic TRALI; however, the sample size of
our study is more than sufficient to study short- and long-
term postoperative outcome and the more common perioper-
ative pulmonary dysfunction presumed to be the conse-
quence of cumulated less extreme pulmonary insults.
Although our data do not allow for assessment of timing be-
tween plasma transfusion and the onset of pulmonary dys-
function or the existence of pulmonary overload or
leukocyte antibody status, even if details of these events
were known, disentangling the relative importance of nu-
merous potential contributors to a burden of pulmonary dys-
function is difficult. For example, postoperative plasma
transfusion may compound an already established cardio-
pulmonary bypass-related ischemic lung insult, without
clear evidence of synchronous timing between transfusion
and pulmonary dysfunction. The majority of plasma admin-
istration to patients undergoing cardiac surgery occurs early
postoperatively to treat coagulopathy, and tracheal extuba-
tion typically occurs within hours of surgery and is contin-
gent on cessation of bleeding; thus, recognition of
significant pulmonary dysfunction is likely to follow plasma
transfusion in almost every case.
Aprotinin use and transfusion of other plasma-containing
products (eg, platelets, cryoprecipitate) was not accounted
for in our analysis but occurred infrequently and at similar
rates between groups. Adjustment for patient characteristics
that differed between groups in our male versus female-only
plasma recipient analysis (Table 1) did not eliminate the
observed association of male-only plasma with pulmonary
dysfunction (P ¼ .04) and death or prolonged hospital stay
(P ¼ .007). Ideally, our analysis would have included the
pregnancy history of female plasma donors and the gender
of transfused platelet units (especially those apheresis units
with high plasma volume); unfortunately, parity data were
not available, and platelet doses at our institution are often
pooled from multiple donors. However, our study does
closely simulate the current policy regarding plasma that1358 The Journal of Thoracic and Cardiovascular Surexcludes female donor plasma regardless of donor parity.
Strengths of our analysis compared with previous studies in-
clude assessment of a large, well-characterized population
involving long-term follow-up and the relative reproducibil-
ity of the physiologic stress of elective cardiac surgery com-
pared with previous studies involving heterogeneous
populations of critically ill patients and patients undergoing
emergency surgery.
Interpreting our study findings requires speculation on
a plausible biologic foundation. Clinical data from studies,
such as Palfi and colleagues,18 highlights the rationale for
limiting the use of female donor plasma. In a randomized
double-blind crossover study, these authors compared in-
flammatory mediators and oxygenation in 100 critically ill
patients with transfusion of plasma from multiparous versus
non-multiparous donors. Multiparous plasma was associ-
ated with poorer oxygenation, higher tumor necrosis
factor-a levels, and 4 (vs 1) transfusion reactions. The path-
ophysiology presumed to be operative in Palfi and col-
leagues’ study involves leukocyte antibody-mediated
mechanisms. Leukocyte antibodies are most common in
multiparous women (25%) but are often detected in nullip-
arous women (8%).19 However, constituents other than
leukocyte antibodies have also been implicated in plasma-
related lung injury through effects involving modification
or activation of inflammation (eg, cytokines, soluble CD40
ligand, and lysophosphatidylcholine).4,5,20,21 Although fe-
male donor leukocyte antibodies may be the most important
mediator of catastrophic TRALI,22,23 the relative signifi-
cance of this and alternate mechanisms in mediating other
harmful effects of plasma transfusion are largely unknown.
Profound proinflammatory stimuli, such as cardiopulmo-
nary bypass,20 are an unavoidable aspect of cardiac surgery
that may influence the effects of harmful mediators in trans-
fused plasma. Although inflammatory mediators have not
been investigated with regard to gender-related differences
in stored plasma, cytokine effects in men have been linked
with excess postoperative pulmonary dysfunction.24,25 It is
plausible that lung dysfunction mediated by leukocyte anti-
bodies may be the most easily recognized (ie, lethal) mech-
anism,22,23 but this does not prevent injury mediated by
other plasma-related mechanisms being cumulatively equiv-
alent or more important.5
Although our data are intriguing, they neither support nor
refute blood systems decisions to limit the use of female
plasma to reduce TRALI. However, our study is one of
only a few to assess outcomes related to this policy change
and does provide retrospective data that expose potentially
concerning effects that suggest that such a change may
have an impact on outcomes other than TRALI in patients
undergoing cardiac surgery. Patients undergoing cardiac
surgery are a highly monitored well-documented and size-
able subset of high-risk plasma recipients who may represent
an ideal patient group for ongoing assessment of changes ingery c December 2010
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Mtransfusion policy. Although our study involves data from
before the implementation of a ‘‘male only’’ plasma policy,
in this case the policy being assessed has already been imple-
mented. However, future assessment of changes in blood
management could occur before their clinical introduction.
The few cohort studies investigating changes in the
plasma supply and outcome do not yet provide an endorse-
ment for the policy of restricting use of female donor plasma.
Continuing study of this problem will also require agree-
ment on the most relevant measure of benefit and improved
patient care, including whether blood bank-reported cata-
strophic TRALI, or more common pulmonary events that
meet the standard definition of TRALI, are satisfactory or
sufficient end points to measure success.1,5,26
CONCLUSIONS
Our matched analysis of transfused patients undergoing
aortocoronary bypass surgery found more pulmonary dys-
function and an increased risk of prolonged hospital stay
or death in those receiving exclusively male compared
with female donor plasma. These observations do not sup-
port exclusion of female donor plasma as a method to im-
prove outcome or reduce postoperative pulmonary
dysfunction for transfused patients undergoing cardiac sur-
gery. Outcome studies are an essential part of assessment
of any change in practice, including the supply of blood
components. Confirmation of our findings and those of sim-
ilar studies of critically ill patients should be sought in anal-
yses of additional large datasets and randomized trials.
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APPENDIX 1. Society of Thoracic Surgery and Duke Databank for Cardiovascular Diseases definitions of postcardiac surgery complications
Respiratory
Pulmonary edema Dyspnea, rales, and radiographic findings compatible with edema
Pneumonia Radiographic infiltrate and growth of typical respiratory pathogen or heavy growth of atypical respiratory pathogen
ARDS arterial oxygen tension<50 mm Hg despite inspired oxygen fraction>0.5 or pulmonary capillary wedge pressure
<18 mm Hg
Cardiac
Atrial or ventricular arrhythmia Arrhythmia requiring cardioversion or medications
Cardiac arrest Advanced cardiac life support in the postoperative period
Neurologic
Stroke Loss of neurologic function by ischemia abrupt onset lasting>24 h with residual neurologic signs
Transient ischemic attack Loss of neurologic function by ischemia abrupt onset lasting for<24 h
Infectious
Positive blood culture Positive blood culture in the postoperative period
Leg wound infection Incisional infection requiring dressings and intravenous antibiotics
Sternal wound infection Incisional infection requiring dressings and intravenous antibiotics
Mediastinitis Documented infection without return to operating room
ARDS, Acute respiratory distress syndrome.
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